Risultati di ricerca
James Patrick Allison (born August 7, 1948) [4] is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center in Houston, Texas. [5]
James Patrick Allison (Alice, 7 agosto 1948) è un immunologo statunitense. Direttore del Cancer Research Laboratory dell'Università della California a Berkeley, dal 2012 è docente di Immunologia allo University of Texas M. D. Anderson Cancer Center.
Dr. James Allison is Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, Executive Director of the... Read More.
James P. Allison. The Nobel Prize in Physiology or Medicine 2018. Born: 7 August 1948, Alice, TX, USA. Affiliation at the time of the award: Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Summary
- Can Our Immune Defense Be Engaged For Cancer Treatment?
- Accelerators and Brakes in Our Immune System
- A New Principle For Immune Therapy
- Discovery of PD-1 and Its Importance For Cancer Therapy
- Immune Checkpoint Therapy For Cancer Today and in The Future
- Key Publications
Cancer kills millions of people every year and is one of humanity’s greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor cells this year’s Nobel Laureates have established an entirely new principle for cancer therapy. James P. Allison studied a known protein that functions as a brake on the immune sys...
Cancer comprises many different diseases, all characterized by uncontrolled proliferation of abnormal cells with capacity for spread to healthy organs and tissues. A number of therapeutic approaches are available for cancer treatment, including surgery, radiation, and other strategies, some of which have been awarded previous Nobel Prizes. These in...
The fundamental property of our immune system is the ability to discriminate “self” from “non-self” so that invading bacteria, viruses and other dangers can be attacked and eliminated. T cells, a type of white blood cell, are key players in this defense. T cells were shown to have receptors that bind to structures recognized as non-self and such in...
During the 1990s, in his laboratory at the University of California, Berkeley, James P. Allison studied the T-cell protein CTLA-4. He was one of several scientists who had made the observation that CTLA-4 functions as a brake on T cells. Other research teams exploited the mechanism as a target in the treatment of autoimmune disease. Allison, howeve...
In 1992, a few years before Allison’s discovery, Tasuku Honjo discovered PD-1, another protein expressed on the surface of T-cells. Determined to unravel its role, he meticulously explored its function in a series of elegant experiments performed over many years in his laboratory at Kyoto University. The results showed that PD-1, similar to CTLA-4,...
After the initial studies showing the effects of CTLA-4 and PD-1 blockade, the clinical development has been dramatic. We now know that the treatment, often referred to as “immune checkpoint therapy”, has fundamentally changed the outcome for certain groups of patients with advanced cancer. Similar to other cancer therapies, adverse side effects ar...
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J., 11(11), 3887–3895. Leach, D. R., Krummel, M. F., & Allison, J. P. (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science, 271(5256), 1734–1736. Kwon, E. D., ...
1 ott 2018 · James Allison at the University of Texas MD Anderson Cancer Center in Houston and Tasuku Honjo at Kyoto University in Japan will share the 9 million Swedish kronor (US$1 million) prize. The pair...
Biographical. As a basic scientist, I have been fortunate to see my research findings translate into a powerful new potentially curative treatment strategy for cancer. The first patient I met was Sharon Belvin. I met her in 2006 at Memorial Sloan-Kettering Cancer Center (MSKCC).
